Medications Development Centers of Excellence Cooperative Program (U54)

Post Date

January 31st 2014

Application Due Date

April 25th 2014

Funding Opportunity Number

RFA-DA-15-003

CFDA Number(s)

93.279

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Education
Health

Number of Awards

2

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $3000000

• Award Range:

  $None - $None

Grant Description

This FOA solicits Specialized Center Cooperative Agreement (U54) applications to provide support for Medications Development Centers of Excellence (MDCE) with emphasis solely on clinical research directed towards the identification, evaluation, and development of safe and effective medications and biologics for treatment of substance use disorders (SUDs). Research may focus on both currently approved or novel investigational products. Centers may have a translational project to reinforce rationale of medications for testing. Any preclinical work proposed must be specifically devoted to the reinforcement of rationale of medications planned for clinical testing during the life of the project.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-15-003.html